Recommendations for antithrombotic therapy following TAVI
| AHA/ACC guidelines | ESC/EACTS guidelines | ACC expert consensus | |
| Early after TAVI | Aspirin 75–100 mg/day+clopidogrel 75 mg/day for 6 months (IIb) | Low-dose aspirin+thienopyridine | Aspirin 75–100 mg/day+clopidogrel 75 mg/day for 3–6 months |
| VKA to achieve an INR of 2.5 for at least 3 months in patients at low risk of bleeding (IIb) (newly added from 2017) | For patients with AF, VKA+aspirin or thienopyridine (it should be weighed against increased risk of bleeding) | Consider VKA (INR 2.0–2.5) if at risk of AF or VTE for 3 months | |
| Late after TAVI | Lifelong aspirin 75–100 mg/day (IIb) | Aspirin or thienopyridine alone | Lifelong aspirin 75–100 mg/day |
AF, atrial fibrillation; AHA/ACC, American Heart Association/American College of Cardiology; ESC/EACTS, European Society of Cardiology and European Association of Cardio-Thoracic Surgery; INR, international normalised ratio; VKA, vitamin K antagonist; TAVI, transcatheter aortic valve implantation; VTE, venous thromboembolism.